Formulations of enzalutamide

US12502357B2 · 12/23/2025

FIG. 1 · Sheet 1

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Full text

2 sections

Abstract This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Official name

Formulations of enzalutamide

Publication number

US12502357B2

Inventor / creator

Douglas Alan Lorenz

Assignee / owner

Astellas Pharma Inc.

Filing

12/04/2024

Publication

12/23/2025

Expiry

12/04/2044

Status

ACTIVE

No articles yet — metadata is still available from the registry.

0 replies · cite patents with ^

Join the discussion

No comments yet.